PATENT CLAIM ANALYSIS

Application Number: 15577212
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-05
Patent Classification: ["435", "226000"]

Abstract:
A process for producing blood coagulation factor VII in 3 human cell lines (HepG2, Sk-Hep, HKB-11) and to select the best recombinant protein producer. The murine line BHK-21 was used as control. The data allow to assert that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest of stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter showed to be able to produce rFVII more efficiently, which allows to conclude that human cell lines are a great alternative for the production of recombinant blood coagulation factors.

Claim (Index 11):
The process according to  claim 3 , wherein the transfection uses a polyethylamine reagent and three plasmids are transfected in the following ratio: 10 to 25 ug, preferably 20 \u03bcg vector with the transgene\u2014p1054-rFVII; 10 to 15 ug, preferably 13 \u03bcg pCMV\u0394R8.91; 5 to 10 ug, preferably 7 \u03bcg pMD2 VSVG.

Metadata:
- Claim Count in Document: 6.0
- Percentile: 88.0
- Lexical Diversity: 1.64935
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13981446', '11342299', '12095514', '12823382', '14176330']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6297891757666398
- 35 USC 102 Novelty (BERT): 0.5135286654016166
- Combined Prediction Score: 0.6181631247301376
- Mean Citation Score: 257.67116
- Max Citation Score: 289.90796
- Similarity Product: 192.5401251414824

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test